

**FACTOR**  
THERAPEUTICS

**Broker Meets Biotech**  
**September 2017**



Dr. Rosalind Wilson  
CEO



# Disclaimer

- The information contained in the presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares in any jurisdiction.
- No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained in this document or opinions expressed in the course of this presentation. The information contained in this presentation is subject to change without notification.
- This presentation contains forward-looking statements which can be identified by the use of words such as “may”, “should”, “will”, “expect”, “anticipate”, “believe”, “estimate”, “intend”, “scheduled” or “continue” or similar expressions. Any forward-looking statements contained in this presentation are subject to significant risks, uncertainties, assumptions, contingencies and other factors (many of which are outside the control of, and unknown to Factor Therapeutics Limited, and its officers, employees, agents or associates), which may cause the actual results or performance to be materially different from any future result so performed, expressed or implied by such forward-looking statements.
- There can be no assurance or guarantee that actual outcomes will not differ materially from these statements. The photographs of clinical subjects used in this presentation are illustrative of medical conditions associated with potential applications of VF-001.
- Actual clinical results may vary from those shown.

# Market Overview



Substantial shareholders	% Issued Capital
Allan Gray Investment Management	13.3%
Acorn Capital	8.6%
Fidelity Investment Management	7.7%

▲ **\$0.060**

(As of September 5, 2017)

**\$0.035 (Placement)**

(March 18, 2017)


**Mkt. Cap. A\$45.26m**

(As of September 5, 2017)

Focus	Advanced wound care
Clinical Stage	Phase II US Pivotal EU
Issued Shares	730,042,783
Options	9.5m
Current Cash	AUD ~\$10m
Symbol	FTT
Exchange	ASX
Research coverage	Morgans and Taylor Collison

# Our Technology: Targeting Growth Factors to the Wound

Our technology moves a wound toward a more normalised healing process by combining elements of two naturally-occurring substances




## **Vitronectin**

- Binds to collagen in the wound bed
- Provides a scaffold for skin cells to attach and move into the area to begin the healing process

## **Growth Factor (IGF-1)**

- Signal to stimulate skin cells to move into the wound and multiply

# Robust Pipeline



## VENOUS LEG ULCER

Preparing for End Of Phase 2 meeting (US) and return to CE Mark process (EU)



## DIABETIC FOOT ULCER

Engaged with potential clinical collaborators  
IND package available



## OCULAR (PCED<sup>1</sup>)

PCED is an orphan indication  
Potential for rapid transition into clinical development



## NEW OPPORTUNITIES

Monash collaboration in Harlequin Ichthyosis  
Other orphan indications

PC Ph1 Ph2 Ph3

VF001 (lead)

1. Persistent corneal epithelial defect




# What is a Venous Leg Ulcer?


A **Venous Leg Ulcer (VLU)** is a wound between the knee and ankle that is slow to heal because of problems with blood flow in the veins

## Risk factors for VLU include

- Previous blood clot in the leg (DVT)
- Varicose veins
- Obesity
- Poor mobility e.g. age, arthritis, surgery




# The Silent Epidemic of VLU – Major Commercial Opportunity




# A Potential Game-Changer

- VF001 is targeted to help patients whose ulcers do not heal with standard treatment
- Little cost-benefit for more expensive &/or invasive treatments
- VF001 is a cost-effective treatment that can be used in the community setting – a potential game changer



# Prior clinical data supports Phase 2 trial design


- Early clinical trial – the VitroCARD study - conducted in 2012
- Wound size was significantly reduced after 12 weeks of treatment





# Clinical Trial: Precision Medicine for VLUs


All patients receive standard care<sup>1</sup> during screening, treatment and follow-up



1. Moisture dressings and compression bandaging  
2. 24 sites at 7<sup>th</sup> July

# VF00102 Trial Status

- 280 patients pre-screened and 450 patient visits<sup>1</sup>
- All sites actively seeking patients – high level of engagement
- Enrolment increasing steadily



- Pre-screening helping to focus on the population of interest
- High patient compliance with only one withdrawal
- Still targeting full enrolment this year


# VLU Value Inflection Points

## Near-term catalysts

- Recruitment update – early October
- Targeting to finish recruitment in Q4

## A successful Phase 2 outcome is a major inflection point

- Increases potential of early partnering deal
- Serves as a second pivotal study for potential CE Mark resubmission
- Enables go/no go decision for progression to Phase 3 pivotal studies



# Experienced Management Team

## **Dr Rosalind Wilson, CEO**

Dr Wilson's career has spanned a variety of senior leadership and advisory roles, from small, innovation-led businesses, to global biopharma, including strategy and portfolio management roles at F.Hoffman-LaRoche (Roche Australia, UK and Switzerland), and Business Manager at NucleusX.

## **Mr Nigel Johnson, COO**

Mr Johnson has broad experience in manufacturing, supply chain management, quality, R&D and regulatory affairs. He has been involved in delivering multiple regulated products from a blank sheet of paper into manufacturing, including leading the clinical translation of five recombinant proteins.

## **Dr Gary Shooter, Director of R&D**

Dr Gary Shooter is an experienced Protein Chemist and has a proven track record in the GMP manufacture and characterisation of protein-based therapeutics and products. Prior to joining the company, Dr Shooter was a Senior Research Fellow and Leader of the Tissue Repair and Regeneration Program at QUT.

## **Ms Saskia Jo, Director of Finance**

Ms Jo has over 10 years' commercial experience in finance and compliance. She has been with the Company since 2011 and in addition to her financial management roles, serves as Company Secretary.

## **Mr Anthony Bishop, Project Director**

Mr Bishop gained experience in a wide range of drug development and management roles. He previously worked for Quintiles in Australia and Asia in business development and project management roles, as well as leading drug development projects at CSL, Chakra Biotech and MerLion Pharmaceuticals.

## **Mr Michael Larcom, Director of Quality**

Mr Larcom is an experienced Quality Assurance (QA) professional in the pharmaceutical and medical device industries. He has key skills in pharmaceutical formulation and process development, internal and external audits (FDA, TGA and other third party audits), supplier relationship management, CAPA, validation, quality systems and start up.

# Board of Directors

## Dr Cherrell Hirst, Chair

Dr Hirst has had a distinguished clinical career in the detection and diagnosis of breast cancer and extensive and respected achievements as a director of multiple commercial, government and not-for-profit organisations. In addition she chairs the Advisory Board of the Institute of Molecular Biosciences at UQ.

## Mr Timothy Hughes, NED

Mr Timothy Hughes has over 30 years' experience in senior roles in the investment management and investment banking industries, including roles as Chief Investment Officer at Rothschild Australia and Catholic Super. Mr Hughes currently sits on the Investment Advisory Panel of HESTA and on the Advisory Board of the Centre for Investor Education.

## Dr Christian Behrenbruch, NED

Dr Christian Behrenbruch has over 15 years of healthcare executive leadership experience, including roles as CEO (and executive director) at Mirada Solutions, CTI Molecular Imaging, and ImaginAb, Inc. Dr Behrenbruch is currently the CEO of Telix Pharmaceuticals Limited.

## Mr John Michailidis, NED

Mr. Michailidis is currently the Managing Director for TEVA Australia/NZ and has spent the last 30 years of his career across a range of commercial pharmaceutical companies, such as AviPep and Orphan Australia (acquired by Sigma).

## Dr Robert Ryan

Dr. Ryan has more than 27 years of research, pharmaceutical and biotech experience, spanning the global development process across wide variety of regulatory and clinical activities. Dr. Ryan is currently the President and CEO of Innova Therapeutics, and prior to this position held senior management roles at Scioderm, Roche, Bristol-Myers Squibb (BMS) and Pfizer.

# Investment Summary

- **Addressing a large unmet market need through precision medicine**
  - Global chronic wound care market is a multi-\$Bn opportunity
  - We are treating a large, underserved group of patients who are easily identifiable and for whom VF001 is most likely to show maximum benefit
- **Superior product performance**
  - Wound healing for patients who have “failed” standard treatment; improvements in pain and Quality of Life
- **Validated platform technology**
  - Lead product VF001 has demonstrated potency and safety
  - Pipeline of follow-on products
- **Near-term catalysts and “blue sky” potential**





[www.factor-therapeutics.com](http://www.factor-therapeutics.com)

For more information contact:

Dr. Rosalind Wilson

[r.wilson@factor-therapeutics.com](mailto:r.wilson@factor-therapeutics.com)

